Cargando…
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study
BACKGROUND: Antibody responses to SARS-CoV-2 vaccination are impaired in people with multiple sclerosis (MS) under anti-CD20 therapies. It is however unclear, whether patients who received the basic immunization prior to anti-B cell medication start respond to the COVID-19 booster dose, once B cells...
Autores principales: | Moser, Tobias, Otto, Ferdinand, O'Sullivan, Ciara, Hitzl, Wolfgang, Pilz, Georg, Harrer, Andrea, Trinka, Eugen, Wipfler, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785406/ https://www.ncbi.nlm.nih.gov/pubmed/35093840 http://dx.doi.org/10.1016/j.msard.2022.103560 |
Ejemplares similares
-
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
por: Moser, Tobias, et al.
Publicado: (2022) -
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
por: Moser, Tobias, et al.
Publicado: (2021) -
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
por: Harrer, Christine, et al.
Publicado: (2021) -
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study
por: Pilz, Georg, et al.
Publicado: (2019) -
Chemokine CXCL13 in serum, CSF and blood–CSF barrier function: evidence of compartment restriction
por: Pilz, Georg, et al.
Publicado: (2020)